In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 4 SUPPL. S1, 2000, Pages 23-27

  Rittenhouse, Stephen ^a,b   McCloskey, Lynn ^a   Broskey, John ^a   Niconovich, Nancy ^a   Jakielaszek, Charles ^a   Poupard, James ^a   Coleman, Ken ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Microbiology Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BETA LACTAM; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GEMIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; SULFAMETHOXAZOLE; TRIMETHOPRIM; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; NAPHTHYRIDINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0034128545     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Physician Drug and Diagnosis Audit (PDDA). (1999). January 1998-December 1998. Scott-Levin, Inc. Newtown, PA, USA.
2. Jacobs, M. R. (1997). Respiratory tract infection: epidemiology and surveillance. Journal of Chemotherapy 9, Suppl. 3, 10-17.
3. Grüneberg, R. N. & Felmingham, D. (1996). Results of the Alexander Project: A continuing, multi-center study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagnostic Microbiology and Infectious Disease 25, 169-81.
4. Doern G. V., Brueggemann, A., Holley, H. P. & Rauch, A. M. (1996). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 1208-13.
5. Thornsberry C., Ogilvie, P., Kahn, J. & Mauriz, Y. (1997). Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagnostic Microbiology and Infectious Disease 29, 249-57.
6. Tomeh, M. O., Starr, S. E., McGowan, J. E., Terry, P. M. & Nahmias, A. J. (1974). Ampicillin-resistant Haemophilus influenzae type B infection. Journal of the American Medical Association 229, 295-7.
7. Khan, W., Ross, S., Rodriguez, W., Controni, G. & Saz, A. (1974). Haemophilus influenzae type B resistant to ampicillin. A report of two cases. Journal of the American Medical Association 229, 298-301.
8. Doern, G. V., Jorgensen, J. H., Thornsberry, C. & Preston, D. A. (1986). Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagnostic Microbiology and Infectious Disease 4, 95-107.
9. Rittenhouse, S. F., Miller, L. A., Kaplan, R. L., Mosely, G. H. & Poupard, J. A. (1995). A survey of β-lactamase-producing Haemophilus influenzae. An evaluation of 57500 isolates. Diagnostic Microbiology and Infectious Disease 21, 223-5.
10. Doern, G. V., Jones, R. N., Pfaller, M. A. & Krugler, K. (1999). Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy 43, 385-9.
11. Jorgensen, J. H., Doern, G. V., Maher, L. A., Howell, A. W. & Redding, J. S. (1990). Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy 34, 2075-80.
12. Washington, J. A. (1996). A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994. The Alexander Project Group. Diagnostic Microbiology and Infectious Disease 25, 183-90.
13. Berry, V., Thorburn, C. E., Knott, S. J. & Woodnutt, G. (1998). Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrobial Agents and Chemotherapy 42, 3193-9.
14. Cormican, M. G. & Jones, R. (1997). Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrobial Agents and Chemotherapy 41, 204-11.
15. Pfaller, M. A., Jones, R. N., Doern, G. V. & Kugler, K. (1998). Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy 42, 1762-70.
16. Ballow, C. H., Jones, R. N., Johnson, D. M., Deinhart, J. A. & Schentag J. J. (1997). Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. Diagnostic Microbiology and Infectious Disease 29, 173-86.
17. Mortensen, J. E., Jacobs, M. R. & Koeth, L. M. (1998). Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae in 1997: results of a hospital-based study. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract C-19, p. 74. American Society for Microbiology, Washington, DC.
18. Sensititre susceptibility system technical product information. (1998). Non-Fastidious Procedure. AccuMed International, Inc., Westlake, OH.
19. Sensititre susceptibility system technical product information. (1998). Haemophilus influenzae Procedure. AccuMed International, Inc., Westlake, OH.
20. National Committee for Clinical Laboratory Standards. (1999). Performance Standards for Antimicrobial Susceptibility Testing -Ninth Informational Supplement: M100-S9. NCCLS, Wayne, PA.
21. Moore, T., Niconovich, N. & Coleman K. (1998). SB-265805 (LB20304a): In-vitro antibacterial activity against the common respiratory tract pathogens Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract F-98, p. 257. American Society for Microbiology, Washington, DC.
22. Broskey, J., Coleman, K., Gwynn, M. N., McCloskey, L., Traini, C., Voelker, L. et al. (2000). Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 45, Suppl. S1, 95-99.
23. Morrisey, I. and George, J. T. (2000). Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. Journal of Antimicrobial Chemotherapy 45, Suppl. S1, 101-106.